(New York Times) – Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare and Medicaid are not eligible.

Novo Nordisk will cut the price of its blockbuster weight loss medication Wegovy to $499 per month for certain patients who pay using their own money instead of going through insurance, the drug maker said on Wednesday. (Read More)